Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of trastuzumab rezeteccan plus adebrelimab in ADC and immunotherapy-resistant advanced urothelial carcinoma
ChiCTR2600133387Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan and adebrelimab in transitional cell carcinoma (TCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Radiographic progression-free survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanadebrelimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2600133387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133387.